Claims‐based studies of oral glucose‐lowering medications can achieve balance in critical clinical variables only observed in electronic health records
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Aim: To evaluate the extent to which balance in unmeasured characteristics of patients with type 2 diabetes (T2DM) was achieved in claims data, by comparing against more detailed information from linked electronic health records (EHR) data. Methods: Within a large US commercial insurance database and using a cohort design, we identified patients with T2DM initiating linagliptin or a comparator agent within class (ie, another dipeptidyl peptidase‐4 inhibitor) or outside class (ie, pioglitazone or a sulphonylurea) between May 2011 and December 2012. We focused on comparators used at a similar stage of diabetes to linagliptin. For each comparison, 1:1 propensity score (PS) matching was used to balance >100 baseline claims‐based characteristics, including proxies of diabetes severity and duration. Additional clinical data from EHR were available for a subset of patients. We assessed representativeness of the claims–EHR‐linked subset, evaluated the balance of claims‐ and EHR‐based covariates before and after PS‐matching via standardized differences (SDs), and quantified the potential bias associated with observed imbalances. Results: From a claims‐based study population of 166 613 patients with T2DM, 7219 (4.3%) patients were linked to their EHR data. Claims‐based characteristics in the EHR‐linked and EHR‐unlinked patients were similar (SD < 0.1), confirming the representativeness of the EHR‐linked subset. The balance of claims‐based and EHR‐based patient characteristics appeared to be reasonable before PS‐matching and generally improved in the PS‐matched population, to be SD < 0.1 for most patient characteristics and SD < 0.2 for select laboratory results and body mass index categories, which was not large enough to cause meaningful confounding. Conclusion: In the context of pharmacoepidemiological research on diabetes therapy, choosing appropriate comparison groups paired with a new‐user design and 1:1 PS matching on many proxies of diabetes severity and duration improves balance in covariates typically unmeasured in administrative claims datasets, to the extent that residual confounding is unlikely.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Austin, P. C. (2009) · Statistics in Medicine · doi:10.1002/sim.3697 · Cited by 6,758 · cited 1×
“1.(24) In a secondary analysis, we quantified the potential bias associated with observed imbalances, through hypothetical scenarios built on varying assumptions of exposure–outcome and confounder– outcome associations.”
BackgroundSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Romano, P. S., Roos, L. L., & Jollis, J. G. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90103-8 · Cited by 1,717
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646 · cited 1×
“ensures that baseline covariates are assessed before treatment initiation and are not affected by treatment itself.(12,28) These choices resulted in fair balance in EHR-based covariates even before PS-matching, as a testament to the major role played by a proper study design for the achievement of overall study validi…”
BackgroundSchneeweiss, S., Rassen, J. A., Glynn, R. J., Avorn, J., Mogun, H., & Brookhart, M. A. (2009) · Epidemiology · doi:10.1097/ede.0b013e3181a663cc · Cited by 1,128
Cited by
Franklin, J. M., Patorno, E., Desai, R. J., Glynn, R. J., Martin, D., Quinto, K., Pawar, A., Bessette, L. G., Lee, H., Garry, E. M., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051718 · Cited by 299
Self-citationPatorno, E., Pawar, A., Franklin, J. M., Najafzadeh, M., Déruaz-Luyet, A., Brodovicz, K. G., Sambevski, S., Bessette, L. G., Santiago Ortiz, A. J., Kulldorff, M., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.039177 · Cited by 215
Self-citationFranklin, J. M., Pawar, A., Martin, D., Glynn, R. J., Levenson, M., Temple, R., & Schneeweiss, S. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1633 · Cited by 119
Self-citationPatorno, E., Htoo, P. T., Glynn, R. J., Schneeweiss, S., Wexler, D. J., Pawar, A., Bessette, L. G., Chin, K., Everett, B. M., & Kim, S. C. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0893 · Cited by 103
“However, in a previous study, we showed that a new user, active comparator cohort study design paired with the adjustment for a large number of claims-based confounder proxies ensured sufficient balance in many characteristics typically unmeasured in claims data (41).”
BackgroundSelf-citationFralick, M., Kim, S. C., Schneeweiss, S., Everett, B. M., Glynn, R. J., & Patorno, E. (2020) · BMJ · doi:10.1136/bmj.m2812 · Cited by 63
Self-citation
Metadata
- Authors
- Patorno, E., Gopalakrishnan, C., Franklin, J. M., Brodovicz, K. G., Masso‐Gonzalez, E., Bartels, D. B., Liu, J., & Schneeweiss, S.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2018-01-12
- Volume
- 20
- Issue
- 4
- Pages
- 974-984
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2773101798
- Cited by
- 84
- References
- 11
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Claims‐based studies of oral glucose‐lowering medications can achieve balance in critical clinical variables only observed in electronic health records. https://app.cochat.ai/papers/10.1111/dom.13184
- The paper
- Patorno, E., Gopalakrishnan, C., Franklin, J. M., Brodovicz, K. G., Masso‐Gonzalez, E., Bartels, D. B., Liu, J., & Schneeweiss, S. (2018). Claims‐based studies of oral glucose‐lowering medications can achieve balance in critical clinical variables only observed in electronic health records. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13184
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.